Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Cytokinetics, Inc.    CYTK

CYTOKINETICS, INC.

(CYTK)
  Report  
Real-time Quote. Real-time Cboe BZX - 05/22 04:00:00 pm
10.615 USD   -1.62%
05/09CYTOKINETICS : 1Q Earnings Snapshot
AQ
05/09CYTOKINETICS : Reports First Quarter 2019 Financial Results
AQ
05/08CYTOKINETICS : to Hold Annual Meeting of Stockholders
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

CYTOKINETICS INC : Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/10/2018 | 04:18pm EDT

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

As previously disclosed in the Current Report on Form 8-K filed on October 27, 2017, Cytokinetics, Incorporated (the "Company") entered into a Second Amendment (the "Amendment") to that certain loan and security agreement (the "Original Loan Agreement") dated October 19,2015 with Oxford Finance LLC ("Oxford"), as the collateral agent and a lenders party thereto.

On August 8, 2018, following the satisfaction of certain conditions related to Phase 2 data for reldesemtiv in spinal muscular atrophy specified in the Amendment, the Company drew an additional $10.0 million.

In connection with Term Loan C, the Company issued to the Lenders warrants exercisable for 42,253 shares of the Company's common stock (the "Warrants"). The Warrants are exercisable in whole or in part, immediately, and have a per share price of $7.10, which was calculated based on the methodology provided in the Agreement.

The foregoing is only a summary of the material terms of the Agreement and the Warrants, and does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement and the Warrants.

Item 3.02 Unregistered Sales of Equity Securities.

The information set forth under Item 2.03 above that relates to the issuance of the Warrants is hereby incorporated by reference into Item 3.02.

The Warrants described in Item 2.03 above were offered and sold in reliance upon the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended (the "Securities Act"). The Warrants contain representations to support the Company's reasonable belief that each of the recipients of such securities had access to information concerning the Company's operations and financial condition, that each such recipient is acquiring the securities for its own account and not with a view to the distribution thereof, and that each such recipient is an "accredited investor" as defined by Rule 501 promulgated under the Securities Act.

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CYTOKINETICS, INC.
05/21CYTOKINETICS INC : Entry into a Material Definitive Agreement, Termination of a ..
AQ
05/17CYTOKINETICS INC : Submission of Matters to a Vote of Security Holders (form 8-K..
AQ
05/17CYTOKINETICS INC : Change in Directors or Principal Officers (form 8-K)
AQ
05/09CYTOKINETICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND R..
AQ
05/09CYTOKINETICS : 1Q Earnings Snapshot
AQ
05/09CYTOKINETICS INC : Results of Operations and Financial Condition (form 8-K)
AQ
05/09CYTOKINETICS : Reports First Quarter 2019 Financial Results
AQ
05/08CYTOKINETICS : to Hold Annual Meeting of Stockholders
AQ
05/06CYTOKINETICS INC : Other Events (form 8-K)
AQ
05/06CYTOKINETICS, INC. : quaterly earnings release
More news
Financials ($)
Sales 2019 30,2 M
EBIT 2019 -87,0 M
Net income 2019 -104 M
Finance 2019 200 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 13,4x
EV / Sales 2020 14,6x
Capitalization 604 M
Chart CYTOKINETICS, INC.
Duration : Period :
Cytokinetics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CYTOKINETICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 15,0 $
Spread / Average Target 43%
EPS Revisions
Managers
NameTitle
Robert I. Blum President, Chief Executive Officer & Director
L. Patrick Gage Chairman
Ching Jaw Chief Financial Officer & Senior Vice President
Andrew A. Wolff Chief Medical Officer & Senior Vice President
John Tannahill Henderson Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CYTOKINETICS, INC.70.73%604
GILEAD SCIENCES6.35%83 745
VERTEX PHARMACEUTICALS2.06%42 447
REGENERON PHARMACEUTICALS-17.01%32 595
GENMAB12.27%10 632
SAREPTA THERAPEUTICS INC11.05%8 718